Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in <scp>BRAF</scp> ‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and <scp>BRAF</scp> / <scp>MEK</scp> Inhibitors: A Case Report

We report a rare case of cholangiocarcinoma with suspected EBV-associated HLH that developed after sequential therapy with an ICI and BRAF/MEK inhibitors. Clinicians should consider HLH as a differential diagnosis in patients with a history of ICI therapy who present with severe unexplained inflammation or shock. Prompt diagnosis and multidisciplinary management are crucial to prevent death.